[Previous Months][Date Index][Thread Index][Join - Register][Login]
  [Message Prev][Message Next][Thread Prev][Thread Next]

[IP] amylin study



I just received the January issue of Diabetes Care in todays mail.  On page
1 is an article about pramlintide (amylin).  Pramlintide is an analog of the
beta-cell hormone amylin.

John Kinsley
Type 1 - 1956
MiniMed 507 - 1998
---------------------------------------------

OBJECTIVETo assess the effects of adjunctive treatment with pramlintide, an
analog of the _-cell hormone amylin, on 24-h glucose fluctuations and
postprandial glucose, glucagon, and triglyceride excursions in patients with
type 1 diabetes intensively treated with continuous subcutaneous insulin
infusion (CSII).

RESULTSAt baseline, patients had excessive 24-h glucose fluctuations, with
59% of the CGMS measurements >140 mg/dl, 13% <80 mg/dl, and only 28% in the
euglycemic range (80140 mg/dl).  After 4 weeks on pramlintide, measurements
in the hyperglycemic range declined to 48% and measurements within the
euglycemic range increased to 37%.  This shift from the hyperglycemic to the
euglycemic range occurred with a concomitant 17% reduction in mealtime
insulin dosages and without relevant increases in measurements below the
euglycemic range (15%) or any severe hypoglycemic events.  After 4 weeks on
pramlintide, postprandial glucose, glucagon, and triglyceride excursions
were reduced by  86,  87, and  72%, respectively (incremental areas under
the curve, all P < 0.05 vs. baseline).  At week 6 (off treatment), the 24-h
glucose profile and postprandial glucose, glucagon, and triglyceride
excursions approached pretreatment values.

CONCLUSIONSIn this study, the addition of pramlintide to insulin therapy
reduced excessive 24-h glucose fluctuations as well as postprandial glucose,
glucagon, and triglyceride excursions in patients with type 1 diabetes
intensively treated with insulin pumps.
----------------------------------------------------------
for HELP or to subscribe/unsubscribe, contact:
HELP@insulin-pumpers.org